IGF1 and Duchenne muscular dystrophy: Promising preclinical results led to a clinical trial where recombinant IGF-1 (rhIGF-1, Increlex, an FDA-approved drug for growth failure) was administered subcutaneously in glucocorticoid-treated DMD boys for 6 months.